ID   HXK4_HUMAN              Reviewed;         465 AA.
AC   P35557; A4D2J2; A4D2J3; Q05810;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   10-MAY-2017, entry version 188.
DE   RecName: Full=Glucokinase;
DE            EC=2.7.1.2;
DE   AltName: Full=Hexokinase type IV;
DE            Short=HK IV;
DE   AltName: Full=Hexokinase-4;
DE            Short=HK4;
DE   AltName: Full=Hexokinase-D;
GN   Name=GCK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1354840; DOI=10.1210/mend.6.7.1354840;
RA   Tanizawa Y., Matsutani A., Chiu K.C., Permutt M.A.;
RT   "Human glucokinase gene: isolation, structural characterization, and
RT   identification of a microsatellite repeat polymorphism.";
RL   Mol. Endocrinol. 6:1070-1081(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-107.
RX   PubMed=1871135; DOI=10.1073/pnas.88.16.7294;
RA   Tanizawa Y., Koranyi L.I., Welling C.M., Permutt M.A.;
RT   "Human liver glucokinase gene: cloning and sequence determination of
RT   two alternatively spliced cDNAs.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:7294-7297(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=1511800;
RA   Nishi S., Stoffel M., Xiang K.S., Shows T.B., Bell G.I., Takeda J.;
RT   "Human pancreatic beta-cell glucokinase: cDNA sequence and
RT   localization of the polymorphic gene to chromosome 7, band p13.";
RL   Diabetologia 35:743-747(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=1612194; DOI=10.2337/diab.41.7.807;
RA   Koranyi L.I., Tanizawa Y., Welling C.M., Rabin D.U., Permutt M.A.;
RT   "Human islet glucokinase gene. Isolation and sequence analysis of
RT   full-length cDNA.";
RL   Diabetes 41:807-811(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MODY2 MET-228 AND
RP   ARG-261.
RC   TISSUE=Placenta;
RX   PubMed=1502186; DOI=10.1073/pnas.89.16.7698;
RA   Stoffel M., Froguel P., Takeda J., Zouali H., Vionnet N., Nishi S.,
RA   Weber I.T., Harrison R.W., Pilkis S.J., Lesage S., Vaxillaire M.,
RA   Velho G., Sun F., Iris F., Passa P., Cohen D., Bell G.I.;
RT   "Human glucokinase gene: isolation, characterization, and
RT   identification of two missense mutations linked to early-onset non-
RT   insulin-dependent (type 2) diabetes mellitus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:7698-7702(1992).
RN   [6]
RP   ERRATUM.
RA   Stoffel M., Froguel P., Takeda J., Zouali H., Vionnet N., Nishi S.,
RA   Weber I.T., Harrison R.W., Pilkis S.J., Lesage S., Vaxillaire M.,
RA   Velho G., Sun F., Iris F., Passa P., Cohen D., Bell G.I.;
RL   Proc. Natl. Acad. Sci. U.S.A. 89:10562-10562(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT THR-107, AND VARIANT MODY2
RP   ARG-261.
RX   PubMed=1464666; DOI=10.1210/jcem.75.6.1464666;
RA   Sakura H., Eto K., Kadowaki H., Simokawa K., Ueno H., Koda N.,
RA   Fukushima Y., Akanuma Y., Yazaki Y., Kadowaki T.;
RT   "Structure of the human glucokinase gene and identification of a
RT   missense mutation in a Japanese patient with early-onset non-insulin-
RT   dependent diabetes mellitus.";
RL   J. Clin. Endocrinol. Metab. 75:1571-1573(1992).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   ENZYME REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=10456334; DOI=10.1016/S0014-5793(99)00971-0;
RA   de la Iglesia N., Veiga-da-Cunha M., Van Schaftingen E.,
RA   Guinovart J.J., Ferrer J.C.;
RT   "Glucokinase regulatory protein is essential for the proper
RT   subcellular localisation of liver glucokinase.";
RL   FEBS Lett. 456:332-338(1999).
RN   [13]
RP   INTERACTION WITH MIDN, AND SUBCELLULAR LOCATION.
RX   PubMed=24187134; DOI=10.1074/jbc.M113.526632;
RA   Hofmeister-Brix A., Kollmann K., Langer S., Schultz J., Lenzen S.,
RA   Baltrusch S.;
RT   "Identification of the ubiquitin-like domain of midnolin as a new
RT   glucokinase interaction partner.";
RL   J. Biol. Chem. 288:35824-35839(2013).
RN   [14]
RP   3D-STRUCTURE MODELING.
RX   PubMed=8194664; DOI=10.2337/diab.43.6.784;
RA   St Charles R., Harrison R.W., Bell G.I., Pilkis S.J., Weber I.T.;
RT   "Molecular model of human beta-cell glucokinase built by analogy to
RT   the crystal structure of yeast hexokinase B.";
RL   Diabetes 43:784-791(1994).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 16-465 OF APOPROTEIN AND IN
RP   COMPLEX WITH GLUCOSE, SUBUNIT, AND ENZYME REGULATION.
RX   PubMed=15016359; DOI=10.1016/j.str.2004.02.005;
RA   Kamata K., Mitsuya M., Nishimura T., Eiki J., Nagata Y.;
RT   "Structural basis for allosteric regulation of the monomeric
RT   allosteric enzyme human glucokinase.";
RL   Structure 12:429-438(2004).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 16-465 IN COMPLEX WITH
RP   SYNTHETIC ALLOSTERIC ACTIVATOR.
RX   PubMed=19362831; DOI=10.1016/j.bmcl.2009.03.137;
RA   Mitsuya M., Kamata K., Bamba M., Watanabe H., Sasaki Y., Sasaki K.,
RA   Ohyama S., Hosaka H., Nagata Y., Eiki J., Nishimura T.;
RT   "Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide
RT   derivatives as GK activators.";
RL   Bioorg. Med. Chem. Lett. 19:2718-2721(2009).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 3-465 IN COMPLEX WITH RAT
RP   GKRP.
RX   PubMed=23957911; DOI=10.1021/bi400838t;
RA   Beck T., Miller B.G.;
RT   "Structural basis for regulation of human glucokinase by glucokinase
RT   regulatory protein.";
RL   Biochemistry 52:6232-6239(2013).
RN   [18]
RP   VARIANT MODY2 ARG-299.
RX   PubMed=1303265; DOI=10.1038/ng1092-153;
RA   Stoffel M., Patel P., Lo Y.-M.D., Hattersley A.T., Lucassen A.M.,
RA   Page R., Bell J.I., Bell G.I., Turner R.C., Wainscoat J.S.;
RT   "Missense glucokinase mutation in maturity-onset diabetes of the young
RT   and mutation screening in late-onset diabetes.";
RL   Nat. Genet. 2:153-156(1992).
RN   [19]
RP   VARIANT THR-11.
RX   PubMed=8454109; DOI=10.2337/diab.42.4.579;
RA   Chiu K.C., Tanizawa Y., Permutt M.A.;
RT   "Glucokinase gene variants in the common form of NIDDM.";
RL   Diabetes 42:579-582(1993).
RN   [20]
RP   VARIANT MODY2 PRO-131.
RX   PubMed=8495817; DOI=10.2337/diab.42.6.937;
RA   Stoffel M., Bell K.L., Blackburn C.L., Powell K.L., Seo T.S.,
RA   Takeda J., Vionnet N., Xiang K.-S., Gidh-Jain M., Pilkis S.J.,
RA   Ober C., Bell G.I.;
RT   "Identification of glucokinase mutations in subjects with gestational
RT   diabetes mellitus.";
RL   Diabetes 42:937-940(1993).
RN   [21]
RP   VARIANT ASN-4, AND VARIANTS MODY2 LYS-70; PRO-131; THR-188; ARG-257
RP   AND GLU-414.
RX   PubMed=8325892;
RA   Takeda J., Gidh-Jain M., Xu L.Z., Froguel P., Velho G., Vaxillaire M.,
RA   Cohen D., Shimada F., Makino H., Nishi S., Stoffel M., Vionnet N.,
RA   St Charles R., Harrison R.W., Weber I.T., Bell G.I., Pilkis S.J.;
RT   "Structure/function studies of human beta-cell glucokinase. Enzymatic
RT   properties of a sequence polymorphism, mutations associated with
RT   diabetes, and other site-directed mutants.";
RL   J. Biol. Chem. 268:15200-15204(1993).
RN   [22]
RP   CHARACTERIZATION OF VARIANTS MODY2.
RX   PubMed=8446612; DOI=10.1073/pnas.90.5.1932;
RA   Gidh-Jain M., Takeda J., Xu L.Z., Lange A.J., Vionnet N., Stoffel M.,
RA   Froguel P., Velho G., Sun D., Cohen D., Patel P., Lo Y.-M.D.,
RA   Hattersley A.T., Luthman H., Wedell A., St Charles R., Harrison R.W.,
RA   Weber I.T., Bell G.I., Pilkis S.J.;
RT   "Glucokinase mutations associated with non-insulin-dependent (type 2)
RT   diabetes mellitus have decreased enzymatic activity: implications for
RT   structure/function relationships.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:1932-1936(1993).
RN   [23]
RP   VARIANTS MODY2 TRP-36; MET-209 AND GLU-261.
RX   PubMed=8168652; DOI=10.2337/diab.43.5.730;
RA   Hager J., Blanche H., Sun F., Vionnet N., Vaxillaire M., Poller W.,
RA   Cohen D., Czernichow P., Velho G., Robert J.-J., Cohen N., Froguel P.;
RT   "Six mutations in the glucokinase gene identified in MODY by using a
RT   nonradioactive sensitive screening technique.";
RL   Diabetes 43:730-733(1994).
RN   [24]
RP   VARIANTS MODY2.
RX   PubMed=9049484; DOI=10.1007/s001250050666;
RA   Velho G., Blanche H., Vaxillaire M., Bellanne-Chantelot C.,
RA   Pardini V.C., Timsit J., Passa P., Deschamps I., Robert J.-J.,
RA   Weber I.T., Marotta D., Pilkis S.J., Lipkind G.M., Bell G.I.,
RA   Froguel P.;
RT   "Identification of 14 new glucokinase mutations and description of the
RT   clinical profile of 42 MODY-2 families.";
RL   Diabetologia 40:217-224(1997).
RN   [25]
RP   VARIANTS MODY2 SER-80; LYS-221 AND CYS-227.
RX   PubMed=10694920;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:2<136::AID-HUMU13>3.3.CO;2-M;
RA   Guazzini B., Gaffi D., Mainieri D., Multari G., Cordera R.,
RA   Bertolini S., Pozza G., Meschi F., Barbetti F.;
RT   "Three novel missense mutations in the glucokinase gene (G80S; E221K;
RT   G227C) in Italian subjects with maturity-onset diabetes of the young
RT   (MODY).";
RL   Hum. Mutat. 12:136-136(1998).
RN   [26]
RP   VARIANTS MODY2 HIS-108; SER-150; THR-259; ARG-299; TYR-382; THR-384
RP   AND CYS-392.
RX   PubMed=9662401; DOI=10.1038/953;
RA   Hattersley A.T., Beards F., Ballantyne E., Appleton M., Harvey R.,
RA   Ellard S.;
RT   "Mutations in the glucokinase gene of the fetus result in reduced
RT   birth weight.";
RL   Nat. Genet. 19:268-270(1998).
RN   [27]
RP   VARIANT HHF3 MET-455.
RX   PubMed=9435328; DOI=10.1056/NEJM199801223380404;
RA   Glaser B., Kesavan P., Heyman M., Davis E., Cuesta A., Buchs A.,
RA   Stanley C.A., Thornton P.S., Permutt M.A., Matschinsky F.M.,
RA   Herold K.C.;
RT   "Familial hyperinsulinism caused by an activating glucokinase
RT   mutation.";
RL   N. Engl. J. Med. 338:226-230(1998).
RN   [28]
RP   VARIANTS MODY2 THR-110; ASP-119 AND VAL-385.
RX   PubMed=10588527; DOI=10.1046/j.1464-5491.1999.00188.x;
RA   Ng M.C.Y., Cockburn B.N., Lindner T.H., Yeung V.T.F., Chow C.-C.,
RA   So W.-Y., Li J.K.Y., Lo Y.M.D., Lee Z.S.K., Cockram C.S.,
RA   Critchley J.A.J.H., Bell G.I., Chan J.C.N.;
RT   "Molecular genetics of diabetes mellitus in Chinese subjects:
RT   identification of mutations in glucokinase and hepatocyte nuclear
RT   factor-1alpha genes in patients with early-onset type 2 diabetes
RT   mellitus/MODY.";
RL   Diabet. Med. 16:956-963(1999).
RN   [29]
RP   VARIANT MODY2 PRO-164.
RX   PubMed=11106831; DOI=10.1016/S0168-8227(00)00191-1;
RA   Nam J.H., Lee H.C., Kim Y.H., Cha B.S., Song Y.D., Lim S.K., Kim K.R.,
RA   Huh K.B.;
RT   "Identification of glucokinase mutation in subjects with post-renal
RT   transplantation diabetes mellitus.";
RL   Diabetes Res. Clin. Pract. 50:169-176(2000).
RN   [30]
RP   VARIANTS MODY2 LYS-210 AND MET-228.
RX   PubMed=11372010; DOI=10.1056/NEJM200105243442104;
RA   Njoelstad P.R., Soevik O., Cuesta-Munoz A., Bjoerkhaug L., Massa O.,
RA   Barbetti F., Undlien D.E., Shiota C., Magnuson M.A., Molven A.,
RA   Matschinsky F.M., Bell G.I.;
RT   "Neonatal diabetes mellitus due to complete glucokinase deficiency.";
RL   N. Engl. J. Med. 344:1588-1592(2001).
RN   [31]
RP   VARIANT HHF3 ILE-65, AND CHARACTERIZATION OF VARIANT HHF3 ILE-65.
RX   PubMed=12941786;
RA   Gloyn A.L., Noordam K., Willemsen M.A., Ellard S., Lam W.W.,
RA   Campbell I.W., Midgley P., Shiota C., Buettger C., Magnuson M.A.,
RA   Matschinsky F.M., Hattersley A.T.;
RT   "Insights into the biochemical and genetic basis of glucokinase
RT   activation from naturally occurring hypoglycemia mutations.";
RL   Diabetes 52:2433-2440(2003).
RN   [32]
RP   VARIANTS MODY2 TRP-36; TYR-129; LEU-152; VAL-188; TRP-191; ARG-202;
RP   SER-223; MET-226; HIS-231; PHE-315; THR-378; PHE-434; TRP-441 AND
RP   GLN-447.
RX   PubMed=16965331; DOI=10.1111/j.1399-0004.2006.00686.x;
RA   Vits L., Beckers D., Craen M., de Beaufort C., Vanfleteren E.,
RA   Dahan K., Nollet A., Vanhaverbeke G., Imschoot S.V., Bourguignon J.P.,
RA   Beauloye V., Storm K., Massa G., Giri M., Nobels F., De Schepper J.,
RA   Rooman R., Van den Bruel A., Mathieu C., Wuyts W.;
RT   "Identification of novel and recurrent glucokinase mutations in
RT   Belgian and Luxembourg maturity onset diabetes of the young
RT   patients.";
RL   Clin. Genet. 70:355-359(2006).
RN   [33]
RP   VARIANT MODY2 TRP-441, CHARACTERIZATION OF VARIANT MODY2 TRP-441,
RP   VARIANT HHF3 LYS-442, AND CHARACTERIZATION OF VARIANT HHF3 LYS-442.
RX   PubMed=19884385; DOI=10.1210/me.2009-0094;
RA   Barbetti F., Cobo-Vuilleumier N., Dionisi-Vici C., Toni S.,
RA   Ciampalini P., Massa O., Rodriguez-Bada P., Colombo C., Lenzi L.,
RA   Garcia-Gimeno M.A., Bermudez-Silva F.J., Rodriguez de Fonseca F.,
RA   Banin P., Aledo J.C., Baixeras E., Sanz P., Cuesta-Munoz A.L.;
RT   "Opposite clinical phenotypes of glucokinase disease: Description of a
RT   novel activating mutation and contiguous inactivating mutations in
RT   human glucokinase (GCK) gene.";
RL   Mol. Endocrinol. 23:1983-1989(2009).
RN   [34]
RP   VARIANT HHF3 LEU-91, AND CHARACTERIZATION OF VARIANT HHF3 LEU-91.
RX   PubMed=20375417; DOI=10.1056/NEJMc0909845;
RA   Kassem S., Bhandari S., Rodriguez-Bada P., Motaghedi R., Heyman M.,
RA   Garcia-Gimeno M.A., Cobo-Vuilleumier N., Sanz P., Maclaren N.K.,
RA   Rahier J., Glaser B., Cuesta-Munoz A.L.;
RT   "Large islets, beta-cell proliferation, and a glucokinase mutation.";
RL   N. Engl. J. Med. 362:1348-1350(2010).
RN   [35]
RP   ERRATUM.
RA   Kassem S., Bhandari S., Rodriguez-Bada P., Motaghedi R., Heyman M.,
RA   Garcia-Gimeno M.A., Cobo-Vuilleumier N., Sanz P., Maclaren N.K.,
RA   Rahier J., Glaser B., Cuesta-Munoz A.L.;
RL   N. Engl. J. Med. 363:2178-2178(2010).
RN   [36]
RP   VARIANT PRO-342.
RX   PubMed=21604084; DOI=10.1007/s00125-011-2194-5;
RA   Steele A.M., Tribble N.D., Caswell R., Wensley K.J., Hattersley A.T.,
RA   Gloyn A.L., Ellard S.;
RT   "The previously reported T342P GCK missense variant is not a
RT   pathogenic mutation causing MODY.";
RL   Diabetologia 54:2202-2205(2011).
RN   [37]
RP   VARIANTS MODY2 HIS-43; ASP-68; ASN-217; MET-225; LYS-248; ARG-261 AND
RP   ARG-261, CHARACTERIZATION OF VARIANTS MODY2 HIS-43; ASP-68; ASN-217;
RP   MET-225; LYS-248; ARG-261 AND ARG-261, AND MUTAGENESIS OF ASP-217;
RP   ILE-225 AND GLU-248.
RX   PubMed=22611063; DOI=10.2337/dc11-2420;
RA   Beer N.L., Osbak K.K., van de Bunt M., Tribble N.D., Steele A.M.,
RA   Wensley K.J., Edghill E.L., Colcough K., Barrett A., Valentinova L.,
RA   Rundle J.K., Raimondo A., Grimsby J., Ellard S., Gloyn A.L.;
RT   "Insights into the pathogenicity of rare missense GCK variants from
RT   the identification and functional characterization of compound
RT   heterozygous and double mutations inherited in cis.";
RL   Diabetes Care 35:1482-1484(2012).
RN   [38]
RP   VARIANTS HHF3 ILE-65; LEU-91; CYS-99 AND LYS-442, AND CHARACTERIZATION
RP   OF VARIANT HHF3 CYS-99.
RX   PubMed=28247534; DOI=10.1111/cen.13318;
RG   Spanish Congenital Hyperinsulinism Group;
RA   Martinez R., Gutierrez-Nogues A., Fernandez-Ramos C., Velayos T.,
RA   Vela A., Navas M.A., Castano L.;
RT   "Heterogeneity in phenotype of hyperinsulinism caused by activating
RT   glucokinase mutations: a novel mutation and its functional
RT   characterization.";
RL   Clin. Endocrinol. (Oxf.) 0:0-0(2017).
CC   -!- FUNCTION: Catalyzes the initial step in utilization of glucose by
CC       the beta-cell and liver at physiological glucose concentration.
CC       Glucokinase has a high Km for glucose, and so it is effective only
CC       when glucose is abundant. The role of GCK is to provide G6P for
CC       the synthesis of glycogen. Pancreatic glucokinase plays an
CC       important role in modulating insulin secretion. Hepatic
CC       glucokinase helps to facilitate the uptake and conversion of
CC       glucose by acting as an insulin-sensitive determinant of hepatic
CC       glucose usage.
CC   -!- CATALYTIC ACTIVITY: ATP + D-glucose = ADP + D-glucose 6-phosphate.
CC   -!- ENZYME REGULATION: The use of alternative promoters apparently
CC       enables the type IV hexokinase gene to be regulated by insulin in
CC       the liver and glucose in the beta cell. This may constitute an
CC       important feedback loop for maintaining glucose homeostasis.
CC       Subject to allosteric regulation. Low glucose and high fructose-6-
CC       phosphate triggers association with the inhibitor GKRP followed by
CC       sequestration in the nucleus. {ECO:0000269|PubMed:10456334,
CC       ECO:0000269|PubMed:15016359}.
CC   -!- SUBUNIT: Monomer (PubMed:15016359, PubMed:19362831,
CC       PubMed:23957911). Interacts with MIDN; the interaction occurs
CC       preferentially at low glucose levels and results in inhibition of
CC       GCK activity (PubMed:24187134). {ECO:0000269|PubMed:15016359,
CC       ECO:0000269|PubMed:19362831, ECO:0000269|PubMed:23957911,
CC       ECO:0000269|PubMed:24187134}.
CC   -!- INTERACTION:
CC       Q14397:GCKR; NbExp=2; IntAct=EBI-709928, EBI-709948;
CC       P16118:PFKFB1; NbExp=2; IntAct=EBI-709928, EBI-709807;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10456334,
CC       ECO:0000269|PubMed:24187134}. Nucleus
CC       {ECO:0000269|PubMed:10456334, ECO:0000269|PubMed:24187134}.
CC       Note=Under low glucose concentrations, GCK associates with GKRP
CC       and the inactive complex is recruited to the hepatocyte nucleus.
CC       {ECO:0000269|PubMed:10456334}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P35557-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P35557-2; Sequence=VSP_002074;
CC       Name=3;
CC         IsoId=P35557-3; Sequence=VSP_002075;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed in pancreas. Isoform 2
CC       and isoform 3 is expressed in liver.
CC   -!- DISEASE: Maturity-onset diabetes of the young 2 (MODY2)
CC       [MIM:125851]: A form of diabetes that is characterized by an
CC       autosomal dominant mode of inheritance, onset in childhood or
CC       early adulthood (usually before 25 years of age), a primary defect
CC       in insulin secretion and frequent insulin-independence at the
CC       beginning of the disease. {ECO:0000269|PubMed:10588527,
CC       ECO:0000269|PubMed:10694920, ECO:0000269|PubMed:11106831,
CC       ECO:0000269|PubMed:11372010, ECO:0000269|PubMed:1303265,
CC       ECO:0000269|PubMed:1464666, ECO:0000269|PubMed:1502186,
CC       ECO:0000269|PubMed:16965331, ECO:0000269|PubMed:19884385,
CC       ECO:0000269|PubMed:22611063, ECO:0000269|PubMed:8168652,
CC       ECO:0000269|PubMed:8325892, ECO:0000269|PubMed:8446612,
CC       ECO:0000269|PubMed:8495817, ECO:0000269|PubMed:9049484,
CC       ECO:0000269|PubMed:9662401}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Familial hyperinsulinemic hypoglycemia 3 (HHF3)
CC       [MIM:602485]: Most common cause of persistent hypoglycemia in
CC       infancy. Unless early and aggressive intervention is undertaken,
CC       brain damage from recurrent episodes of hypoglycemia may occur.
CC       {ECO:0000269|PubMed:12941786, ECO:0000269|PubMed:19884385,
CC       ECO:0000269|PubMed:20375417, ECO:0000269|PubMed:28247534,
CC       ECO:0000269|PubMed:9435328}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: In vertebrates there are four major glucose-
CC       phosphorylating isoenzymes, designated hexokinase I, II, III and
CC       IV (glucokinase).
CC   -!- SIMILARITY: Belongs to the hexokinase family.
CC       {ECO:0000255|PROSITE-ProRule:PRU01084, ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Glucokinase entry;
CC       URL="https://en.wikipedia.org/wiki/Glucokinase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M88011; AAA51824.1; -; mRNA.
DR   EMBL; M69051; AAB59563.1; ALT_SEQ; mRNA.
DR   EMBL; M90298; AAA67541.1; ALT_TERM; Genomic_DNA.
DR   EMBL; M90298; AAA67542.1; ALT_TERM; Genomic_DNA.
DR   EMBL; M90299; AAA52562.1; -; mRNA.
DR   EMBL; AF041022; AAB97680.1; -; Genomic_DNA.
DR   EMBL; AF041012; AAB97680.1; JOINED; Genomic_DNA.
DR   EMBL; AF041015; AAB97680.1; JOINED; Genomic_DNA.
DR   EMBL; AF041016; AAB97680.1; JOINED; Genomic_DNA.
DR   EMBL; AF041017; AAB97680.1; JOINED; Genomic_DNA.
DR   EMBL; AF041018; AAB97680.1; JOINED; Genomic_DNA.
DR   EMBL; AF041019; AAB97680.1; JOINED; Genomic_DNA.
DR   EMBL; AF041020; AAB97680.1; JOINED; Genomic_DNA.
DR   EMBL; AF041021; AAB97680.1; JOINED; Genomic_DNA.
DR   EMBL; AF041022; AAB97681.1; -; Genomic_DNA.
DR   EMBL; AF041013; AAB97681.1; JOINED; Genomic_DNA.
DR   EMBL; AF041015; AAB97681.1; JOINED; Genomic_DNA.
DR   EMBL; AF041016; AAB97681.1; JOINED; Genomic_DNA.
DR   EMBL; AF041017; AAB97681.1; JOINED; Genomic_DNA.
DR   EMBL; AF041018; AAB97681.1; JOINED; Genomic_DNA.
DR   EMBL; AF041019; AAB97681.1; JOINED; Genomic_DNA.
DR   EMBL; AF041020; AAB97681.1; JOINED; Genomic_DNA.
DR   EMBL; AF041021; AAB97681.1; JOINED; Genomic_DNA.
DR   EMBL; AF041022; AAB97682.1; -; Genomic_DNA.
DR   EMBL; AF041014; AAB97682.1; JOINED; Genomic_DNA.
DR   EMBL; AF041015; AAB97682.1; JOINED; Genomic_DNA.
DR   EMBL; AF041016; AAB97682.1; JOINED; Genomic_DNA.
DR   EMBL; AF041017; AAB97682.1; JOINED; Genomic_DNA.
DR   EMBL; AF041018; AAB97682.1; JOINED; Genomic_DNA.
DR   EMBL; AF041019; AAB97682.1; JOINED; Genomic_DNA.
DR   EMBL; AF041020; AAB97682.1; JOINED; Genomic_DNA.
DR   EMBL; AF041021; AAB97682.1; JOINED; Genomic_DNA.
DR   EMBL; AK122876; BAG53774.1; -; mRNA.
DR   EMBL; CH236960; EAL23765.1; -; Genomic_DNA.
DR   EMBL; CH236960; EAL23766.1; -; Genomic_DNA.
DR   EMBL; CH471128; EAW61114.1; -; Genomic_DNA.
DR   EMBL; CH471128; EAW61116.1; -; Genomic_DNA.
DR   EMBL; BC001890; AAH01890.1; -; mRNA.
DR   CCDS; CCDS5479.1; -. [P35557-1]
DR   CCDS; CCDS5480.1; -. [P35557-2]
DR   CCDS; CCDS5481.1; -. [P35557-3]
DR   PIR; A46157; A46157.
DR   PIR; B46157; B46157.
DR   PIR; C46157; C46157.
DR   RefSeq; NP_000153.1; NM_000162.3. [P35557-1]
DR   RefSeq; NP_277042.1; NM_033507.1. [P35557-2]
DR   RefSeq; NP_277043.1; NM_033508.1. [P35557-3]
DR   UniGene; Hs.1270; -.
DR   PDB; 1GLK; Model; -; A=1-465.
DR   PDB; 1V4S; X-ray; 2.30 A; A=16-465.
DR   PDB; 1V4T; X-ray; 3.40 A; A=16-465.
DR   PDB; 3A0I; X-ray; 2.20 A; X=16-465.
DR   PDB; 3F9M; X-ray; 1.50 A; A=12-465.
DR   PDB; 3FGU; X-ray; 2.15 A; A=12-465.
DR   PDB; 3FR0; X-ray; 2.70 A; A=16-465.
DR   PDB; 3GOI; X-ray; 2.52 A; A=16-465.
DR   PDB; 3H1V; X-ray; 2.11 A; X=16-465.
DR   PDB; 3ID8; X-ray; 2.40 A; A=12-465.
DR   PDB; 3IDH; X-ray; 2.14 A; A=12-465.
DR   PDB; 3IMX; X-ray; 2.00 A; A=16-465.
DR   PDB; 3QIC; X-ray; 2.20 A; A=12-465.
DR   PDB; 3S41; X-ray; 2.18 A; A=12-465.
DR   PDB; 3VEV; X-ray; 1.80 A; A=12-465.
DR   PDB; 3VEY; X-ray; 2.25 A; A=16-465.
DR   PDB; 3VF6; X-ray; 1.86 A; A=12-465.
DR   PDB; 4DCH; X-ray; 1.79 A; A=1-465.
DR   PDB; 4DHY; X-ray; 2.38 A; A=12-465.
DR   PDB; 4ISE; X-ray; 1.78 A; A=16-465.
DR   PDB; 4ISF; X-ray; 2.09 A; A=16-465.
DR   PDB; 4ISG; X-ray; 2.64 A; A=16-465.
DR   PDB; 4IWV; X-ray; 2.10 A; A=16-465.
DR   PDB; 4IXC; X-ray; 2.00 A; A=16-465.
DR   PDB; 4L3Q; X-ray; 2.70 A; A=16-465.
DR   PDB; 4LC9; X-ray; 3.40 A; B=3-465.
DR   PDB; 4MLE; X-ray; 2.60 A; A=16-465.
DR   PDB; 4MLH; X-ray; 2.90 A; A=16-465.
DR   PDB; 4NO7; X-ray; 1.70 A; A=12-465.
DR   PDB; 4RCH; X-ray; 2.30 A; A=16-465.
DR   PDBsum; 1GLK; -.
DR   PDBsum; 1V4S; -.
DR   PDBsum; 1V4T; -.
DR   PDBsum; 3A0I; -.
DR   PDBsum; 3F9M; -.
DR   PDBsum; 3FGU; -.
DR   PDBsum; 3FR0; -.
DR   PDBsum; 3GOI; -.
DR   PDBsum; 3H1V; -.
DR   PDBsum; 3ID8; -.
DR   PDBsum; 3IDH; -.
DR   PDBsum; 3IMX; -.
DR   PDBsum; 3QIC; -.
DR   PDBsum; 3S41; -.
DR   PDBsum; 3VEV; -.
DR   PDBsum; 3VEY; -.
DR   PDBsum; 3VF6; -.
DR   PDBsum; 4DCH; -.
DR   PDBsum; 4DHY; -.
DR   PDBsum; 4ISE; -.
DR   PDBsum; 4ISF; -.
DR   PDBsum; 4ISG; -.
DR   PDBsum; 4IWV; -.
DR   PDBsum; 4IXC; -.
DR   PDBsum; 4L3Q; -.
DR   PDBsum; 4LC9; -.
DR   PDBsum; 4MLE; -.
DR   PDBsum; 4MLH; -.
DR   PDBsum; 4NO7; -.
DR   PDBsum; 4RCH; -.
DR   ProteinModelPortal; P35557; -.
DR   SMR; P35557; -.
DR   BioGrid; 108915; 9.
DR   IntAct; P35557; 6.
DR   STRING; 9606.ENSP00000223366; -.
DR   BindingDB; P35557; -.
DR   ChEMBL; CHEMBL3820; -.
DR   DrugBank; DB02379; Beta-D-Glucose.
DR   GuidetoPHARMACOLOGY; 2798; -.
DR   iPTMnet; P35557; -.
DR   PhosphoSitePlus; P35557; -.
DR   BioMuta; GCK; -.
DR   DMDM; 547696; -.
DR   PaxDb; P35557; -.
DR   PeptideAtlas; P35557; -.
DR   PRIDE; P35557; -.
DR   DNASU; 2645; -.
DR   Ensembl; ENST00000345378; ENSP00000223366; ENSG00000106633. [P35557-2]
DR   Ensembl; ENST00000395796; ENSP00000379142; ENSG00000106633. [P35557-3]
DR   Ensembl; ENST00000403799; ENSP00000384247; ENSG00000106633. [P35557-1]
DR   Ensembl; ENST00000616242; ENSP00000482149; ENSG00000106633. [P35557-3]
DR   GeneID; 2645; -.
DR   KEGG; hsa:2645; -.
DR   UCSC; uc003tkj.2; human. [P35557-1]
DR   CTD; 2645; -.
DR   DisGeNET; 2645; -.
DR   GeneCards; GCK; -.
DR   GeneReviews; GCK; -.
DR   HGNC; HGNC:4195; GCK.
DR   HPA; HPA007034; -.
DR   HPA; HPA007093; -.
DR   MalaCards; GCK; -.
DR   MIM; 125851; phenotype.
DR   MIM; 138079; gene.
DR   MIM; 602485; phenotype.
DR   MIM; 606391; phenotype.
DR   neXtProt; NX_P35557; -.
DR   OpenTargets; ENSG00000106633; -.
DR   Orphanet; 79299; Hyperinsulinism due to glucokinase deficiency.
DR   Orphanet; 552; MODY.
DR   Orphanet; 99885; Permanent neonatal diabetes mellitus.
DR   PharmGKB; PA28610; -.
DR   eggNOG; KOG1369; Eukaryota.
DR   eggNOG; COG5026; LUCA.
DR   GeneTree; ENSGT00390000017159; -.
DR   HOGENOM; HOG000162670; -.
DR   HOVERGEN; HBG000142; -.
DR   InParanoid; P35557; -.
DR   KO; K12407; -.
DR   OMA; AHMCGAG; -.
DR   OrthoDB; EOG091G08MD; -.
DR   PhylomeDB; P35557; -.
DR   TreeFam; TF314238; -.
DR   BioCyc; MetaCyc:HS02935-MONOMER; -.
DR   BRENDA; 2.7.1.1; 2681.
DR   BRENDA; 2.7.1.2; 2681.
DR   Reactome; R-HSA-170822; Regulation of Glucokinase by Glucokinase Regulatory Protein.
DR   Reactome; R-HSA-210745; Regulation of gene expression in beta cells.
DR   Reactome; R-HSA-5619107; Defective TRP may confer susceptibility towards thyroid papillary carcinoma (TPC).
DR   Reactome; R-HSA-70153; Glucose transport.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   SABIO-RK; P35557; -.
DR   ChiTaRS; GCK; human.
DR   EvolutionaryTrace; P35557; -.
DR   GeneWiki; Glucokinase; -.
DR   GenomeRNAi; 2645; -.
DR   PRO; PR:P35557; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000106633; -.
DR   CleanEx; HS_GCK; -.
DR   ExpressionAtlas; P35557; baseline and differential.
DR   Genevisible; P35557; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0004340; F:glucokinase activity; IDA:UniProtKB.
DR   GO; GO:0005536; F:glucose binding; IDA:UniProtKB.
DR   GO; GO:0070509; P:calcium ion import; IEA:Ensembl.
DR   GO; GO:0061621; P:canonical glycolysis; TAS:Reactome.
DR   GO; GO:0001678; P:cellular glucose homeostasis; IBA:GO_Central.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:BHF-UCL.
DR   GO; GO:0044320; P:cellular response to leptin stimulus; ISS:BHF-UCL.
DR   GO; GO:0051594; P:detection of glucose; IMP:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; IMP:UniProtKB.
DR   GO; GO:0015758; P:glucose transport; TAS:Reactome.
DR   GO; GO:0006096; P:glycolytic process; IBA:GO_Central.
DR   GO; GO:0006739; P:NADP metabolic process; IEA:Ensembl.
DR   GO; GO:0045721; P:negative regulation of gluconeogenesis; IMP:UniProtKB.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0032024; P:positive regulation of insulin secretion; IMP:UniProtKB.
DR   GO; GO:0010827; P:regulation of glucose transport; TAS:Reactome.
DR   GO; GO:0006110; P:regulation of glycolytic process; NAS:BHF-UCL.
DR   GO; GO:0050796; P:regulation of insulin secretion; IMP:BHF-UCL.
DR   GO; GO:0043266; P:regulation of potassium ion transport; IEA:Ensembl.
DR   InterPro; IPR001312; Hexokinase.
DR   InterPro; IPR019807; Hexokinase_BS.
DR   InterPro; IPR022673; Hexokinase_C.
DR   InterPro; IPR022672; Hexokinase_N.
DR   PANTHER; PTHR19443; PTHR19443; 1.
DR   Pfam; PF00349; Hexokinase_1; 1.
DR   Pfam; PF03727; Hexokinase_2; 1.
DR   PROSITE; PS00378; HEXOKINASE_1; 1.
DR   PROSITE; PS51748; HEXOKINASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Allosteric enzyme; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; Diabetes mellitus; Disease mutation;
KW   Glycolysis; Kinase; Nucleotide-binding; Nucleus; Polymorphism;
KW   Reference proteome; Transferase.
FT   CHAIN         1    465       Glucokinase.
FT                                /FTId=PRO_0000197593.
FT   DOMAIN       10    454       Hexokinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01084}.
FT   NP_BIND      78     83       ATP. {ECO:0000250}.
FT   NP_BIND     295    296       ATP. {ECO:0000250}.
FT   NP_BIND     332    336       ATP. {ECO:0000250}.
FT   NP_BIND     411    415       ATP. {ECO:0000250}.
FT   REGION       67    203       Hexokinase small subdomain.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01084}.
FT   REGION      151    152       Substrate binding.
FT   REGION      168    169       Substrate binding.
FT   REGION      204    443       Hexokinase large subdomain.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01084}.
FT   REGION      204    205       Substrate binding.
FT   BINDING     104    104       ATP. {ECO:0000255}.
FT   BINDING     228    228       ATP. {ECO:0000250}.
FT   BINDING     231    231       Substrate.
FT   BINDING     256    256       Substrate.
FT   BINDING     290    290       Substrate.
FT   VAR_SEQ       1     15       MLDDRARMEAAKKEK -> MAMDVTRSQAQTALTL (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_002074.
FT   VAR_SEQ       1     15       MLDDRARMEAAKKEK -> MPRPRSQLPQPNSQ (in
FT                                isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_002075.
FT   VARIANT       4      4       D -> N (in dbSNP:rs202091228).
FT                                {ECO:0000269|PubMed:8325892}.
FT                                /FTId=VAR_003692.
FT   VARIANT      11     11       A -> T (in dbSNP:rs116093166).
FT                                {ECO:0000269|PubMed:8454109}.
FT                                /FTId=VAR_010583.
FT   VARIANT      36     36       R -> W (in MODY2; dbSNP:rs762263694).
FT                                {ECO:0000269|PubMed:16965331,
FT                                ECO:0000269|PubMed:8168652}.
FT                                /FTId=VAR_010584.
FT   VARIANT      43     43       R -> H (in MODY2; unknown pathological
FT                                significance; no change in glucokinase
FT                                activity; dbSNP:rs764232985).
FT                                {ECO:0000269|PubMed:22611063}.
FT                                /FTId=VAR_075220.
FT   VARIANT      53     53       A -> S (in MODY2).
FT                                /FTId=VAR_010585.
FT   VARIANT      65     65       T -> I (in HHF3; decreased glucokinase
FT                                activity; increased affinity for glucose;
FT                                unchanged affinity for ATP).
FT                                {ECO:0000269|PubMed:12941786,
FT                                ECO:0000269|PubMed:28247534}.
FT                                /FTId=VAR_078243.
FT   VARIANT      68     68       G -> D (in MODY2; unknown pathological
FT                                significance; found in some patients that
FT                                also carry an H-43; mildly increases
FT                                glucokinase activity; dbSNP:rs373418736).
FT                                {ECO:0000269|PubMed:22611063}.
FT                                /FTId=VAR_075221.
FT   VARIANT      70     70       E -> K (in MODY2; large increase in Km
FT                                for glucose).
FT                                {ECO:0000269|PubMed:8325892}.
FT                                /FTId=VAR_003693.
FT   VARIANT      80     80       G -> A (in MODY2).
FT                                /FTId=VAR_003694.
FT   VARIANT      80     80       G -> S (in MODY2).
FT                                {ECO:0000269|PubMed:10694920}.
FT                                /FTId=VAR_003695.
FT   VARIANT      91     91       V -> L (in HHF3; increased glucokinase
FT                                activity; increased affinity for
FT                                glucose). {ECO:0000269|PubMed:20375417,
FT                                ECO:0000269|PubMed:28247534}.
FT                                /FTId=VAR_078244.
FT   VARIANT      99     99       W -> C (in HHF3; increased glucokinase
FT                                activity; increased affinity for glucose;
FT                                increased affinity for ATP).
FT                                {ECO:0000269|PubMed:28247534}.
FT                                /FTId=VAR_078245.
FT   VARIANT     107    107       M -> T. {ECO:0000269|PubMed:1464666,
FT                                ECO:0000269|PubMed:1871135}.
FT                                /FTId=VAR_003696.
FT   VARIANT     108    108       Y -> H (in MODY2).
FT                                {ECO:0000269|PubMed:9662401}.
FT                                /FTId=VAR_010586.
FT   VARIANT     110    110       I -> T (in MODY2).
FT                                {ECO:0000269|PubMed:10588527}.
FT                                /FTId=VAR_012352.
FT   VARIANT     119    119       A -> D (in MODY2).
FT                                {ECO:0000269|PubMed:10588527}.
FT                                /FTId=VAR_012353.
FT   VARIANT     129    129       C -> Y (in MODY2).
FT                                {ECO:0000269|PubMed:16965331}.
FT                                /FTId=VAR_078246.
FT   VARIANT     131    131       S -> P (in MODY2; significant increase in
FT                                the Km and in the affinity for ATP;
FT                                dbSNP:rs104894010).
FT                                {ECO:0000269|PubMed:8325892,
FT                                ECO:0000269|PubMed:8495817}.
FT                                /FTId=VAR_003697.
FT   VARIANT     137    137       H -> R (in MODY2).
FT                                /FTId=VAR_010587.
FT   VARIANT     150    150       F -> S (in MODY2; dbSNP:rs193922297).
FT                                {ECO:0000269|PubMed:9662401}.
FT                                /FTId=VAR_010588.
FT   VARIANT     152    152       F -> L (in MODY2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16965331}.
FT                                /FTId=VAR_078247.
FT   VARIANT     164    164       L -> P (in MODY2).
FT                                {ECO:0000269|PubMed:11106831}.
FT                                /FTId=VAR_012350.
FT   VARIANT     168    168       T -> P (in MODY2).
FT                                /FTId=VAR_010589.
FT   VARIANT     175    175       G -> R (in MODY2; dbSNP:rs587780344).
FT                                /FTId=VAR_003698.
FT   VARIANT     182    182       V -> M (in MODY2; dbSNP:rs587780345).
FT                                /FTId=VAR_003699.
FT   VARIANT     188    188       A -> T (in MODY2; large increase in Km
FT                                for glucose; dbSNP:rs751279776).
FT                                {ECO:0000269|PubMed:8325892}.
FT                                /FTId=VAR_003700.
FT   VARIANT     188    188       A -> V (in MODY2).
FT                                {ECO:0000269|PubMed:16965331}.
FT                                /FTId=VAR_078248.
FT   VARIANT     191    191       R -> W (in MODY2).
FT                                {ECO:0000269|PubMed:16965331}.
FT                                /FTId=VAR_078249.
FT   VARIANT     202    202       M -> R (in MODY2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16965331}.
FT                                /FTId=VAR_078250.
FT   VARIANT     203    203       V -> A (in MODY2).
FT                                /FTId=VAR_003701.
FT   VARIANT     209    209       T -> M (in MODY2).
FT                                {ECO:0000269|PubMed:8168652}.
FT                                /FTId=VAR_010590.
FT   VARIANT     210    210       M -> K (in MODY2; dbSNP:rs80356654).
FT                                {ECO:0000269|PubMed:11372010}.
FT                                /FTId=VAR_012351.
FT   VARIANT     210    210       M -> T (in MODY2).
FT                                /FTId=VAR_010591.
FT   VARIANT     213    213       C -> R (in MODY2).
FT                                /FTId=VAR_010592.
FT   VARIANT     217    217       D -> N (in MODY2; associated with R-261;
FT                                loss of glucokinase activity when
FT                                associated with R-261;
FT                                dbSNP:rs147065275).
FT                                {ECO:0000269|PubMed:22611063}.
FT                                /FTId=VAR_075222.
FT   VARIANT     221    221       E -> K (in MODY2; dbSNP:rs193922317).
FT                                {ECO:0000269|PubMed:10694920}.
FT                                /FTId=VAR_003702.
FT   VARIANT     223    223       G -> S (in MODY2).
FT                                {ECO:0000269|PubMed:16965331}.
FT                                /FTId=VAR_078251.
FT   VARIANT     225    225       I -> M (in MODY2; associated with K-248;
FT                                loss of glucokinase activity when
FT                                associated with K-248).
FT                                {ECO:0000269|PubMed:22611063}.
FT                                /FTId=VAR_075223.
FT   VARIANT     226    226       V -> M (in MODY2; dbSNP:rs148311934).
FT                                {ECO:0000269|PubMed:16965331}.
FT                                /FTId=VAR_003703.
FT   VARIANT     227    227       G -> C (in MODY2).
FT                                {ECO:0000269|PubMed:10694920}.
FT                                /FTId=VAR_003704.
FT   VARIANT     228    228       T -> M (in MODY2; dbSNP:rs80356655).
FT                                {ECO:0000269|PubMed:11372010,
FT                                ECO:0000269|PubMed:1502186}.
FT                                /FTId=VAR_003705.
FT   VARIANT     231    231       N -> H (in MODY2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16965331}.
FT                                /FTId=VAR_078252.
FT   VARIANT     248    248       E -> K (in MODY2; associated with M-225;
FT                                loss of glucokinase activity when
FT                                associated with M-225;
FT                                dbSNP:rs759421263).
FT                                {ECO:0000269|PubMed:22611063}.
FT                                /FTId=VAR_075224.
FT   VARIANT     256    256       E -> K (in MODY2; dbSNP:rs769268803).
FT                                /FTId=VAR_003706.
FT   VARIANT     257    257       W -> R (in MODY2; almost complete loss of
FT                                activity). {ECO:0000269|PubMed:8325892}.
FT                                /FTId=VAR_003707.
FT   VARIANT     259    259       A -> T (in MODY2).
FT                                {ECO:0000269|PubMed:9662401}.
FT                                /FTId=VAR_010593.
FT   VARIANT     261    261       G -> E (in MODY2).
FT                                {ECO:0000269|PubMed:8168652}.
FT                                /FTId=VAR_010594.
FT   VARIANT     261    261       G -> R (in MODY2; associated with N-217
FT                                in some patients; loss of glucokinase
FT                                activity when associated with R-217;
FT                                highly decreases glucokinase activity
FT                                when found as single mutation;
FT                                dbSNP:rs104894008).
FT                                {ECO:0000269|PubMed:1464666,
FT                                ECO:0000269|PubMed:1502186,
FT                                ECO:0000269|PubMed:22611063}.
FT                                /FTId=VAR_003708.
FT   VARIANT     279    279       E -> Q (in MODY2; dbSNP:rs104894005).
FT                                /FTId=VAR_003709.
FT   VARIANT     299    299       G -> R (in MODY2; dbSNP:rs104894009).
FT                                {ECO:0000269|PubMed:1303265,
FT                                ECO:0000269|PubMed:9662401}.
FT                                /FTId=VAR_003710.
FT   VARIANT     300    300       E -> K (in MODY2).
FT                                /FTId=VAR_003712.
FT   VARIANT     300    300       E -> Q (in MODY2).
FT                                /FTId=VAR_003711.
FT   VARIANT     309    309       L -> P (in MODY2).
FT                                /FTId=VAR_003713.
FT   VARIANT     315    315       L -> F (in MODY2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16965331}.
FT                                /FTId=VAR_078253.
FT   VARIANT     336    336       S -> L (in MODY2).
FT                                /FTId=VAR_010595.
FT   VARIANT     342    342       T -> P. {ECO:0000269|PubMed:21604084}.
FT                                /FTId=VAR_066615.
FT   VARIANT     367    367       V -> M (in MODY2).
FT                                /FTId=VAR_010596.
FT   VARIANT     378    378       A -> T (in MODY2).
FT                                {ECO:0000269|PubMed:16965331}.
FT                                /FTId=VAR_078254.
FT   VARIANT     382    382       C -> Y (in MODY2).
FT                                {ECO:0000269|PubMed:9662401}.
FT                                /FTId=VAR_010597.
FT   VARIANT     384    384       A -> T (in MODY2).
FT                                {ECO:0000269|PubMed:9662401}.
FT                                /FTId=VAR_010598.
FT   VARIANT     385    385       G -> V (in MODY2).
FT                                {ECO:0000269|PubMed:10588527}.
FT                                /FTId=VAR_012354.
FT   VARIANT     392    392       R -> C (in MODY2).
FT                                {ECO:0000269|PubMed:9662401}.
FT                                /FTId=VAR_010599.
FT   VARIANT     414    414       K -> E (in MODY2; large increase in Km
FT                                for glucose; dbSNP:rs193922272).
FT                                {ECO:0000269|PubMed:8325892}.
FT                                /FTId=VAR_003714.
FT   VARIANT     434    434       C -> F (in MODY2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16965331}.
FT                                /FTId=VAR_078255.
FT   VARIANT     441    441       S -> W (in MODY2; decreased affinity for
FT                                glucose). {ECO:0000269|PubMed:16965331,
FT                                ECO:0000269|PubMed:19884385}.
FT                                /FTId=VAR_078256.
FT   VARIANT     442    442       E -> K (in HHF3; increased affinity for
FT                                glucose). {ECO:0000269|PubMed:19884385,
FT                                ECO:0000269|PubMed:28247534}.
FT                                /FTId=VAR_078257.
FT   VARIANT     447    447       R -> Q (in MODY2).
FT                                {ECO:0000269|PubMed:16965331}.
FT                                /FTId=VAR_078258.
FT   VARIANT     455    455       V -> M (in HHF3; dbSNP:rs104894012).
FT                                {ECO:0000269|PubMed:9435328}.
FT                                /FTId=VAR_003715.
FT   MUTAGEN     177    177       E->K: Small change in activity.
FT   MUTAGEN     217    217       D->N: Mildly increases glucokinase
FT                                activity. {ECO:0000269|PubMed:22611063}.
FT   MUTAGEN     225    225       I->M: Highly decreases glucokinase
FT                                activity. {ECO:0000269|PubMed:22611063}.
FT   MUTAGEN     248    248       E->K: Highly decreases glucokinase
FT                                activity. {ECO:0000269|PubMed:22611063}.
FT   MUTAGEN     256    256       E->A: Inactive enzyme.
FT   MUTAGEN     414    414       K->A: Small change in activity.
FT   HELIX        12     20       {ECO:0000244|PDB:3F9M}.
FT   HELIX        21     23       {ECO:0000244|PDB:3F9M}.
FT   HELIX        27     45       {ECO:0000244|PDB:3F9M}.
FT   TURN         47     52       {ECO:0000244|PDB:3F9M}.
FT   STRAND       58     65       {ECO:0000244|PDB:3F9M}.
FT   TURN         66     68       {ECO:0000244|PDB:4LC9}.
FT   STRAND       72     92       {ECO:0000244|PDB:3F9M}.
FT   STRAND       95     97       {ECO:0000244|PDB:3H1V}.
FT   STRAND       99    109       {ECO:0000244|PDB:3F9M}.
FT   HELIX       112    115       {ECO:0000244|PDB:3F9M}.
FT   STRAND      116    118       {ECO:0000244|PDB:3F9M}.
FT   HELIX       119    136       {ECO:0000244|PDB:3F9M}.
FT   STRAND      140    142       {ECO:0000244|PDB:3F9M}.
FT   STRAND      145    150       {ECO:0000244|PDB:3F9M}.
FT   STRAND      154    158       {ECO:0000244|PDB:3F9M}.
FT   STRAND      161    164       {ECO:0000244|PDB:3F9M}.
FT   HELIX       181    192       {ECO:0000244|PDB:3F9M}.
FT   STRAND      198    203       {ECO:0000244|PDB:3F9M}.
FT   HELIX       205    214       {ECO:0000244|PDB:3F9M}.
FT   STRAND      220    237       {ECO:0000244|PDB:3F9M}.
FT   HELIX       238    240       {ECO:0000244|PDB:3F9M}.
FT   STRAND      248    254       {ECO:0000244|PDB:3F9M}.
FT   HELIX       257    259       {ECO:0000244|PDB:3F9M}.
FT   TURN        260    263       {ECO:0000244|PDB:3F9M}.
FT   STRAND      264    266       {ECO:0000244|PDB:4MLH}.
FT   HELIX       267    269       {ECO:0000244|PDB:3F9M}.
FT   HELIX       272    280       {ECO:0000244|PDB:3F9M}.
FT   STRAND      281    283       {ECO:0000244|PDB:3F9M}.
FT   HELIX       288    291       {ECO:0000244|PDB:3F9M}.
FT   HELIX       295    311       {ECO:0000244|PDB:3F9M}.
FT   HELIX       316    318       {ECO:0000244|PDB:3F9M}.
FT   TURN        322    325       {ECO:0000244|PDB:3F9M}.
FT   HELIX       332    339       {ECO:0000244|PDB:3F9M}.
FT   STRAND      340    342       {ECO:0000244|PDB:3QIC}.
FT   STRAND      343    345       {ECO:0000244|PDB:4ISE}.
FT   HELIX       346    354       {ECO:0000244|PDB:3F9M}.
FT   HELIX       361    396       {ECO:0000244|PDB:3F9M}.
FT   STRAND      400    409       {ECO:0000244|PDB:3F9M}.
FT   HELIX       411    415       {ECO:0000244|PDB:3F9M}.
FT   STRAND      416    418       {ECO:0000244|PDB:3VEV}.
FT   HELIX       419    430       {ECO:0000244|PDB:3F9M}.
FT   STRAND      434    440       {ECO:0000244|PDB:3F9M}.
FT   HELIX       444    456       {ECO:0000244|PDB:3F9M}.
FT   TURN        457    459       {ECO:0000244|PDB:3H1V}.
SQ   SEQUENCE   465 AA;  52191 MW;  094D4A2F78096724 CRC64;
     MLDDRARMEA AKKEKVEQIL AEFQLQEEDL KKVMRRMQKE MDRGLRLETH EEASVKMLPT
     YVRSTPEGSE VGDFLSLDLG GTNFRVMLVK VGEGEEGQWS VKTKHQMYSI PEDAMTGTAE
     MLFDYISECI SDFLDKHQMK HKKLPLGFTF SFPVRHEDID KGILLNWTKG FKASGAEGNN
     VVGLLRDAIK RRGDFEMDVV AMVNDTVATM ISCYYEDHQC EVGMIVGTGC NACYMEEMQN
     VELVEGDEGR MCVNTEWGAF GDSGELDEFL LEYDRLVDES SANPGQQLYE KLIGGKYMGE
     LVRLVLLRLV DENLLFHGEA SEQLRTRGAF ETRFVSQVES DTGDRKQIYN ILSTLGLRPS
     TTDCDIVRRA CESVSTRAAH MCSAGLAGVI NRMRESRSED VMRITVGVDG SVYKLHPSFK
     ERFHASVRRL TPSCEITFIE SEEGSGRGAA LVSAVACKKA CMLGQ
//
